Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Recruiting now

Conditions studied: Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

In brief

The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

Key facts

Study ID

NCT04290806

Run by

iOMEDICO AG

People needed

1900

Starts

2019-12-04

Expected to finish

2028-12-31

Last updated by the study team

2026-01-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC
• Planned palliative systemic first-line therapy
• Age >= 18 years
• Signed informed consent (IC)
• Patients answering questionnaires: IC before first therapy cycle
• Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle

You may not qualify if…

• No systemic therapy for ESCC, EAC, GAC or GEJAC

Where it is running

• Multiple sites, Gemany — Multiple Locations, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.